Notably, murine studies have shown that montelukast may also modulate the expression of cysteinyl leukotriene receptor 2 (CysLT2-R), suggesting potential therapeutic relevance in CYSLTR2-mutant cancers.6 Here, CYSLTR2 is linked to cancer.